<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02542371</url>
  </required_header>
  <id_info>
    <org_study_id>2014P001832</org_study_id>
    <nct_id>NCT02542371</nct_id>
  </id_info>
  <brief_title>Use of 99mTc Tilmanocept for Imaging Arterial Inflammation</brief_title>
  <official_title>Use of 99mTc Tilmanocept for Imaging Arterial Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Navidea Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Havard University Center for AIDS Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure arterial 99mTc-Tilmanocept uptake using single photon&#xD;
      emission computed tomography (SPECT/CT) scanning in HIV infected subjects known to have&#xD;
      subclinical coronary atherosclerosis as assessed by contrast-enhanced coronary computed&#xD;
      tomography angiography (CCTA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description:&#xD;
&#xD;
      Patients with HIV have been shown to have increased atherosclerotic risk compared to&#xD;
      age-matched controls, and this risk is thought to be related to increased systemic immune&#xD;
      activation. Specifically, systemic immune activation may contribute to destabilizing coronary&#xD;
      atherosclerotic plaque, leading to plaque rupture and myocardial infarction. This study is&#xD;
      intended to measure arterial uptake of the macrophage specific marker 99mTc-Tilmanocept using&#xD;
      single photon emission computed tomography, applied initially to a group of HIV-infected&#xD;
      patients with known subclinical coronary atherosclerosis on CCTA. Moreover, traditional&#xD;
      markers of CVD risk and inflammatory markers will be assessed in relation to CV imaging&#xD;
      outcomes. Positive findings in the index HIV group with known subclinical atherosclerosis&#xD;
      will prompt subsequent study of three comparison groups, as above.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Aortic 99mTc-Tilmanocept uptake on SPECT/CT scanning in HIV Patients</measure>
    <time_frame>within 6 weeks of screening visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aortic plaque burden and morphology on CCTA in HIV Patients</measure>
    <time_frame>within 6 weeks of screening visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Traditional markers of cardiovascular disease (CVD) risk and inflammatory markers in relation to cardiovascular imaging outcomes</measure>
    <time_frame>within 6 weeks of screening visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging assessments in the coronary vasculature in HIV patients</measure>
    <time_frame>within 6 weeks of screening visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of imaging assessments b/ HIV patients w/ known subclinical atherosclerosis, HIV patients w/o known subclinical atherosclerosis, non HIV patients w/ known subclinical atherosclerosis and non HIV patients w/o known subclinical atherosclerosis</measure>
    <time_frame>within 6 weeks of screening visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>99mTc-Tilmanocept uptake on SPECT/CT in regions other than the aorta</measure>
    <time_frame>within 6 weeks of screening visit</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">31</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>HIV infected with known subclinical atherosclerosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV infected without known subclinical atherosclerosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-HIV infected with known subclinical atherosclerosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-HIV infected without known subclinical atherosclerosis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Arterial Imaging</intervention_name>
    <arm_group_label>HIV infected with known subclinical atherosclerosis</arm_group_label>
    <arm_group_label>HIV infected without known subclinical atherosclerosis</arm_group_label>
    <arm_group_label>Non-HIV infected with known subclinical atherosclerosis</arm_group_label>
    <arm_group_label>Non-HIV infected without known subclinical atherosclerosis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, plasma and serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected subjects and HIV non-infected subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        HIV infected subjects with known subclinical atherosclerosis:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  men and women, ages 18+, with documented HIV infection&#xD;
&#xD;
          -  current use of antiretroviral therapy (ART), with no changes to regimen within last 3&#xD;
             months&#xD;
&#xD;
          -  history of subclinical atherosclerosis on CCTA&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  pregnancy or breastfeeding&#xD;
&#xD;
          -  known active opportunistic infection requiring ongoing medical therapy (not including&#xD;
             Hepatitis B/C)&#xD;
&#xD;
          -  CD4 count &lt; 50 cells/mm3&#xD;
&#xD;
          -  history of angina, myocardial infarction, acute coronary syndrome, or coronary artery&#xD;
             stenting or surgery&#xD;
&#xD;
          -  recent and/or current treatment with prescription, systemic steroids or&#xD;
             anti-inflammatory/immune suppressant medical therapies&#xD;
&#xD;
          -  current use of statin or use of statin for &gt; 1 month within the last 6 months&#xD;
&#xD;
          -  known allergy to dextrans and/or DPTA and/or radiometals and/or iodinated contrast&#xD;
             media&#xD;
&#xD;
          -  eGFR &lt; 60 ml/min/1.73 m2 calculated by CDK-EPI&#xD;
&#xD;
          -  contraindications to beta blockers or nitroglycerin&#xD;
&#xD;
          -  significant radiation exposure (&gt;2 CT angiograms) received within the past 12 months&#xD;
&#xD;
          -  BMI &gt; 35 kg/m2 or waist circumference &gt; 70 cm (scanner limitations)&#xD;
&#xD;
        HIV infected subjects without known subclinical atherosclerosis:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  men and women, ages 18+, with documented HIV infection&#xD;
&#xD;
          -  current use of antiretroviral therapy (ART), with no changes to regimen within last 3&#xD;
             months&#xD;
&#xD;
          -  history of clean aorta/ coronaries on CCTA&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - Same as exclusion criteria for HIV infected subjects with known subclinical&#xD;
        atherosclerosis&#xD;
&#xD;
        HIV negative subjects with known subclinical atherosclerosis:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  men and women, ages 18+, without documented HIV infection&#xD;
&#xD;
          -  history of subclinical atherosclerosis on CCTA&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  pregnancy or breastfeeding&#xD;
&#xD;
          -  history of angina, myocardial infarction, acute coronary syndrome, or coronary artery&#xD;
             stenting or surgery&#xD;
&#xD;
          -  recent and/or current treatment with prescription, systemic steroids or&#xD;
             anti-inflammatory/immune suppressant medical therapies&#xD;
&#xD;
          -  current use of statin or use of statin for &gt; 1 month within the last 6 months&#xD;
&#xD;
          -  known allergy to dextrans and/or DPTA and/or radiometals and/or iodinated contrast&#xD;
             media&#xD;
&#xD;
          -  eGFR &lt; 60 ml/min/1.73 m2 calculated by CDK-EPI&#xD;
&#xD;
          -  contraindications to beta blockers or nitroglycerin&#xD;
&#xD;
          -  significant radiation exposure (&gt;2 CT angiograms) received within the past 12 months&#xD;
&#xD;
          -  BMI &gt; 35 kg/m2 or waist circumference &gt; 70 cm (scanner limitations)&#xD;
&#xD;
        HIV negative subjects without known subclinical atherosclerosis:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  men and women, ages 18+, without documented HIV infection&#xD;
&#xD;
          -  history of clean aorta/coronaries on CCTA&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - Same as exclusion criteria for HIV negative subjects with known subclinical&#xD;
        atherosclerosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Grinspoon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven Grinspoon, M.D.</last_name>
    <phone>617-724-9109</phone>
    <email>sgrinspoon@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Grinspoon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Steven Grinspoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 26, 2015</study_first_submitted>
  <study_first_submitted_qc>September 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2015</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Steven K. Grinspoon, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Tilmanocept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

